Skip to content
Innovent Biologics
-
Innovent Biologics to commercialise Daiichi Sankyo’s Vanflyta in China
Vanflyta received approval in China in June 2026 for use in adults with newly diagnosed FLT3-ITD-positive AML, as determined by an appropriate validated diagnostic test.